37th Annual Award Recipient
Fadlo R. Khuri, M.D.
Professor & Chair, Hematology/Oncology
Deputy Director, Winship Cancer Instiute
Emory University School of Medicine
Dr. Khuri delivered his award lecture titled Targeting Survival Signaling in Aerodigestive Cancers
, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Wednesday, April 10, 2013. Visit the AACR Annual Meeting 2013
page for more information on the Annual Meeting.
The Award and Lecture
AACR and the Rosenthal Family Foundation established this award in 1977 to recognize research that has made, or promises to soon make, a notable contribution to improved clinical care in the field of cancer. In its desire to honor and provide incentive to investigators relatively early in their careers, the foundation has stipulated that recipients not be more than 50 years of age at the time the award is received.
The winner of the 37th Annual AACR Richard and Hinda Rosenthal Memorial Award received an honorarium of $10,000, gave a 50-minute lecture during the AACR Annual Meeting 2013 in Washington, DC, USA (April 6-10, 2013), and was given support for the winner and a guest to attend the Annual Meeting.
- Candidacy is open to cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Such institutions include those in academia, industry or government.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
- Candidates must not be more than 50 years of age at the time the award is received. For the 2013 award, a candidate's date of birth must be on or after April 10, 1962.
- Candidates must be engaged in the practice of medicine.
Nomination Procedure and Instructions
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Candidates will be considered by a committee of international cancer leaders appointed by the president of the AACR. After careful deliberations by the Award Committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the award winner will be made on the basis of the candidate's contribution to improved clinical care in the field of cancer. No regard will be given to race, gender, nationality or religious or political views.
Generously supported by the Rosenthal Family Foundation.
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
36th Annual Recipient
Maura L. Gillison, M.D., Ph.D.
Professor of Medicine, Epidemiology, and Otolaryngology
Jeg Coughlin Chair of Cancer Research
The Ohio State University
Dr. Maura L. Gillison (left) delivered her award lecture titled, Clinical Implications of HPV in Head and Neck Cancers, on Wednesday, during the AACR Annual Meeting 2012 in Chicato, IL. Dr. Gillison received her award from AACR immediate Past-President, Dr. Judy E. Garber.
Dr. Maura L. Gillison richly embodies the requirements of this award. Her research involving the biological causes of head and neck squamous cell carcinoma (HNSCC) has transformed the way we think about and treat this disease. Dr. Gillison was the first to define a causal link between human papillomavirus (HPV) and a distinct subset of head and neck cancers. Since this initial finding, her research has further clarified the etiological heterogeneity of head and neck cancers and the impact of this heterogeneity on treatment response and prognosis. Together with colleagues in the cooperative groups, she has demonstrated that tumor HPV status is the single greatest predictor of treatment response and prognosis for head and neck cancer patients. This has led to distinct paths for clinical trial research for HPV-positive HNSCC’s compared to HPV-negative HNSCC’s.
Gillison’s research has also examined the impact of HPV-positive disease at the population level and has identified a rapid increase in incidence for HPV-positive oropharyngeal cancers, which appear to be especially prevalent among Caucasians, men and young adults. These findings have thus shifted our understanding of HPV-associated cancers and has sparked debate over whether young boys and men should be routinely vaccinated against the most common types of HPV. Dr. Gillison, in addition to characterizing the relationship between HPV status and cancer susceptibility, has also pioneered and optimized techniques used to detect oral HPV infection and diagnose HPV-positive cancer. These techniques coupled with epidemiological studies have discovered significant associations among sexual activity and behavior, HPV infections, susceptibility to disease, and survival probability in the event of a cancer diagnosis. In addition to her work at The Ohio State University, Dr. Gillison is further contributing to the understanding and evolution of this field by serving as a principle investigator on the first phase III trial of treatment deintensification for patients with HPV-associated oropharynx cancers, with a goal of maintaining five-year survival rates while reducing the long-term morbidity of therapy.
Dr. Gillison currently serves on the editorial board of several journals including Cancer Prevention Research, Journal of Clinical Oncology, Head and Neck, and Oral Oncology. She is an avid presenter of her research, has participated on numerous advisory boards, organizational committees and grant review panels, and has published over 70 original manuscripts, book chapters, editorials and review articles.